2020
Annual Report to shareholders
31/08/2020Preliminary Final Report
31/08/2020Corporate Governance Statement and Appendix 4G
26/08/2020Investor Presentation – August 2020
18/08/2020Proposed issue of Securities – PIQ
18/08/2020Issue of Corporate Advisory Options and Secondary Trading No
29/07/2020Appendix 4C – June 2020 Quarterly Update
27/07/2020PromarkerD Intellectual Property portfolio expands
30/06/2020Updated Trading Policy
29/06/2020Appendix 3Y – Directors on-market purchase of shares
15/06/2020Appendix 2A – Exercise of Employee Options
14/06/2020Big pharma clinical study validates PromarkerD kidney test
09/06/2020PIQ Investor Presentation – 9th June 2020
25/05/2020Proteomics International receives COVID-19 research grants
28/04/2020Appendix 4C – March 2020 Quarterly Update
16/04/2020CE Mark for PromarkerD Immunoassay Kit
07/04/2020Diagnostics R&D expanded: the Promarker™ Pipeline
31/03/2020Proteomics International expands study with US big pharma
27/03/2020Proposed Issue of Securities
27/03/2020Issue of Corporate Advisory Options
27/03/2020Outcome of Extraordinary General Meeting
23/03/2020Proteomics International to patent biomarkers for diagnosis of endometriosis
27/02/2020PIQ Half Year Report Appendix 4D
10/02/2020PromarkerD presented at Australasian Proteomics conference
30/01/2020Appendix 4C – December 2019 Quarterly Update
14/01/2020CE Mark for PromarkerD Hub predictive software for DKD
